Sansure Biotech Inc.’s Net Profit Dropped 9% in First Three Quarters of 2022

Sansure Biotech Inc. (圣湘生物科技股份有限公司) (688289.SH) reported a net profit of 1.6 billion yuan in the first three quarters of 2022, down 9% year-on-year.

Meanwhile, the company posted 4.1 billion yuan in revenue, up 24.5% year-on-year.

At the end of the reporting period, it had 8.6 billion yuan in total assets and 864.8 million yuan in total liabilities, with a liability-to-asset ratio of 10.1%.